Published by
Throne of Profit EditorialReviewed by
William Hassell
Founder & Chief Editor, Throne of Profit
Every practice runs into the same fork: a sick patient needs bloodwork, and you either run it on your own analyzer in the next twenty minutes or send the sample to a reference lab and wait until tomorrow. Buy the analyzer and you've committed to reagent costs, calibration, and a lease payment whether it runs ten samples a week or a hundred. Send it all out and you're paying per test forever, waiting on results, and sometimes losing the case to a practice down the road that had the answer same-day. The in-house-versus-send-out decision isn't a clinical preference — it's a workflow-and-margin choice that turns entirely on how many of each test you actually run.
Most owners decide this by gut or by whatever the analyzer rep pitched hardest, then never revisit it. That's how a practice ends up with a $30,000 machine running four panels a week, or paying reference-lab prices on a high-volume test it could own for pennies. The math is knowable. It just has to be worked.
ONE TEST TYPE — WHERE'S THE BREAK-EVEN?
low volume break-even high volume
│ │ │
send out ▇▇▇▇░░░░░░░░░░░░░│░░░░░░░░░░░▇▇▇▇ in-house
│ │ │
pay per test, volume that pays own it: low
no equipment off the machine + reagents marginal costOwner symptoms
You own analyzers but aren't sure any of them actually pay for themselves.
Reference-lab invoices keep climbing and you don't know which tests drive them.
Turnaround delays cost you cases, rechecks, or same-day treatment decisions.
Why this happens
Diagnostics get decided one purchase and one send-out at a time, never as a portfolio. An analyzer gets bought because a rep offered a bundle, a colleague liked theirs, or one dramatic case made waiting feel unacceptable — not because the run volume justified the fixed cost. Meanwhile send-out tests accumulate on autopilot; nobody sits down to ask which of them now run often enough to bring in-house. The two channels are never compared on the same page, so the practice carries idle equipment and overpays on volume at the same time.
Common mistakes
Buying the analyzer before counting the volume — committing to fixed costs a low run-rate can't absorb.
Ignoring the all-in per-test cost — reagents, controls, calibration, wasted cartridges, and staff time, not just the headline reagent price.
Treating turnaround as free — a same-day result can change the visit, the treatment, and whether the client comes back.
Never revisiting send-outs — a test that was rare two years ago may now run often enough to own.
Letting the lease drive medicine — running unneeded panels to "justify" the machine instead of the case justifying the test.
Business consequences
The cost of getting this wrong shows up on both sides. Underused equipment bleeds lease and reagent expense against a handful of runs, so each in-house result quietly costs far more than the send-out would have. Over-reliance on the reference lab bleeds the opposite way: high-volume tests at retail per-test pricing, plus lost same-day cases and the goodwill that comes with fast answers. The owner who works the volume-and-cost math routes each test to its cheaper, faster channel — owns the high-volume, time-sensitive tests, sends out the rare and specialized ones — and turns diagnostics from a fuzzy expense into a predictable margin line.
How experienced operators think about it
They think one test type at a time, not "in-house lab" as a single yes-or-no. For each recurring test they hold three numbers in view: how many they run in a typical month, the all-in cost per result on the analyzer (fixed cost spread over that volume, plus every consumable and the staff minutes), and the reference-lab price for the same test. Where owning it beats sending it and the speed matters to the case, it comes in-house. Where volume is thin or the test is specialized, it stays a send-out — the reference lab is carrying the fixed cost for you. Turnaround is treated as real value, not a tiebreaker: same-day answers that change the visit are worth paying for. And the review is recurring, because volumes drift as the practice's case mix changes.
Practical actions
List your recurring tests by volume. Pull a few months of records and rank every test by how often you actually run it. Volume is the first fork.
Compute the all-in per-test cost for each in-house option — spread the equipment and any lease over real monthly volume, then add reagents, controls, calibration, wastage, and staff time.
Put the reference-lab price beside it for the same test, so both channels sit on one page and the cheaper one is obvious.
Price the turnaround. Note which tests drive same-day treatment or repeat visits; speed can justify owning a test the raw cost wouldn't.
Route each test deliberately — own the high-volume, time-sensitive ones, send out the rare and specialized ones — and let the case, not the lease, decide what runs.
Re-run the review yearly. Case mix moves; a send-out that crossed into high volume, or an analyzer that's gone quiet, should change the plan.
This is general business information, not veterinary/clinical or professional advice. Consult a qualified professional for your situation.
Questions every owner should ask
Do I actually know the all-in per-test cost of each analyzer I own?
Which reference-lab tests now run often enough to bring in-house?
Where is a slow turnaround costing me cases or same-day revenue?
Frequently asked questions
How do I know if an analyzer is worth buying before I commit?
Work it backward from volume. Estimate how many of that test you run in a typical month, spread the machine's fixed cost (and lease, if any) over that number, then add every per-run consumable and the staff time. Compare the result to the reference-lab price for the same test. If your real run-rate doesn't push the in-house cost below the send-out price — with some room to spare for the turnaround benefit — the volume isn't there yet. Count first, buy second.
Should turnaround time override the cost math?
Not override it — sit alongside it. For tests that change what happens in the visit, a same-day result has real value: it can drive treatment now, save a recheck, and keep the case in your building instead of losing it to a faster practice. That value can justify owning a test the raw per-run cost alone wouldn't. For tests where waiting a day changes nothing, let cost decide. The point is to price turnaround honestly, not to assume it's either free or priceless.
Related articles
Running a Profitable Veterinary Practice — the pillar.
Handling Euthanasia and End-of-Life Care With Dignity and Order — another workflow-and-margin call.
Opening a Second Clinic Without Breaking the First One — scaling the same decisions across locations.
Why Jobs Take Longer Than You Quoted — the general time-and-cost problem.
Where Time Leaks on a Typical Job — where turnaround and workflow leak margin.
Every business has more decisions than time
Whether you need help solving one problem, evaluating a major opportunity, or making a company-changing decision, Throne of Profit gives you consulting capacity on demand.
Purchase only the consulting capacity you need and use it across Weekly Focus, Strategic Focus, Financial Focus, and ThinkTank engagements.